The Silverman Lab investigates early-life modifiable factors influencing the development and function of the immune system and harnesses these factors to prevent autoimmune diabetes (T1D). The lab discovered that the major histocompatibility complex class II E molecule prevents T1D by shaping the intestinal microbiota early in life. These protective early-life microbes then educate the immune system to prevent autoimmunity.
The Seif Lab is focused on manipulating the human innate and immune systems to treat children with acute lymphoblastic leukemia (ALL). The lab’s long-term goal of the research conducted is to identify innate and adaptive immune mechanisms that can be used to treat pediatric ALL more effectively, and with less toxicity, than existing therapies.